This inventor holds 1 USPTO granted patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2024.
Company Filing History:
1 out of 5,383 
1 out of 1,853 
Years Active: 2024
Title: Susan Boutary: Innovator in Antisense RNA Technology
Introduction
Susan Boutary is a notable inventor based in Arcueil, France. She has made significant contributions to the field of biotechnology, particularly in the development of antisense RNA therapies. Her work focuses on innovative solutions for genetic disorders, showcasing her dedication to advancing medical science.
Latest Patents
Susan Boutary holds a patent for "Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease." This invention relates to antisense RNAs that target PMP22 and can inhibit the expression of this gene by 40% to 60% in cells. The patent emphasizes the use of siRNA, preferably delivered in the form of nanoparticles, to treat Charcot-Marie-Tooth 1A disease effectively.
Career Highlights
Throughout her career, Susan has worked with prestigious organizations such as the Centre National de la Recherche Scientifique and the Institut National de la Santé et de la Recherche Médicale. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of her notable coworkers include Liliane Massade and Charbel Massaad. Their collaborative efforts have further enriched the research environment and fostered innovation in the field of genetic therapies.
Conclusion
Susan Boutary's work in antisense RNA technology represents a significant advancement in the treatment of genetic disorders. Her innovative approach and dedication to research continue to inspire future developments in biotechnology.